In life sciences today, time is the biggest barrier between strategic questions and meaningful answers. Whether launching a new therapy, preparing for label expansion, or navigating market access challenges, medical affairs and commercial teams must quickly understand and navigate how stakeholders perceive and respond to data.
Traditional face-to-face advisory boards have long been the gold standard for gathering expert insight. But they come with high operational costs. Scheduling, travel, honoraria, logistics, and compliance all take months to execute.
But what if you could simulate that expert-level feedback in a matter of weeks? What if you could test multiple scenarios, explore edge cases, and identify gaps before involving live stakeholders?
Two Labs, part of Envision Pharma Group (EPG), has launched the first-of-its-kind simulated advisory board (SAB) service for the emerging biopharma and biotech industries: an AI-powered solution built specifically to support medical affairs, commercial strategy, and evidence planning.
Powered by Posteros and carefully guided by EPG’s strategic consultants, this offering makes it possible to simulate expert-level insight in days, bringing speed, flexibility, and depth when timely answers matter most.
“Our AI platform builds synthetic expert personas grounded in the science and clinical discourse of each therapeutic area — the published debates, the guideline discussions, the real tradeoffs practitioners face. That’s what allows teams to get functionally equivalent insight in days instead of months.”
— Posteros
The problem:
strategic questions that can’t wait
Every day, medical affairs leaders face critical questions that don’t have the luxury of waiting for the next live advisory board.
- Will oncologists view our survival data as clinically meaningful?
- Do nephrologists – or rheumatologists, or cardiologists – see our mechanism of action as truly differentiated?
- How might community-based HCPs respond to our new dosing schedule compared to urban academic centers?
These are the kinds of questions that traditional advisory boards can help answer, but not without significant costs and dedicated time. A typical live advisory board takes two to three months to plan, execute, and analyze. That’s too slow for early signal detection, scenario testing, or internal alignment on emerging data.
And because of their cost, traditional boards are typically limited to one or two per year per brand, meaning key strategic questions can go unanswered for months, or never be explored at all.
The solution:
simulated advisory boards
Simulated advisory boards (SABs) offer a fundamentally new way to get fast, medically rigorous insight by simulating expert behavior and reasoning using synthetic expert personas grounded in published research, treatment guidelines, and documented therapeutic debates within each specialty.
SABs replicate the dynamics of a traditional advisory board, simulating how diverse experts might respond to key questions and clinical scenarios.
“Having executed six traditional advisory boards in 2025, I’ve seen firsthand the contrast between traditional and simulated. The simulated board let us explore strategic angles and challenge assumptions we normally wouldn’t get to in a single live session. It’s a powerful tool for getting clarity early and making live engagements more targeted and productive.”
— Paige Nelson, Senior Principal, Strategic Consulting
How a simulated advisory board works
The SAB process is designed to be fast, secure, and strategic. Here’s what a typical engagement could look like:
- Define the business question: Together with your strategic consulting team, you’ll start by identifying the critical gap in insight or strategy that needs input. From there, the team defines a focused set of strategic questions and selects the characteristics and personas of simulated advisors to ensure relevance across specialties, geographies, and practice types.
- Feed in structured context: Your team provides relevant inputs, which may include target product profiles, clinical trial summaries, competitive data, landscape overviews, or past advisory board outputs. Sensitive or proprietary data is used securely and is not passed to AI models like ChatGPT.
- Simulate stakeholder discussion: The Posteros platform generates simulations of expert agents interacting with the data and each other. These agents are personalized and tailored to emulate diverse disciplines, regions, and practice types and are moderated by our consulting experts to ensure medical accuracy and strategic relevance.
- Analyze and validate: The platform analyzes each response for thematic patterns, sentiment, and points of consensus or divergence – then synthesizes findings. Strategic consultants review and refine these outputs, identifying strategy gaps and translating insights into actionable recommendations.
- Deliver insights: Within a few weeks, you will receive a complete, refined SAB insights report that includes synthesized findings, transcripts of agent dialogue, key recommendations, and optional real-KOL follow-up for validation.
What makes simulated advisory boards valuable
The value of simulated advisory boards lies in their ability to deliver strategic insights faster than traditional advisory boards while testing a much broader range of scenarios. Enhanced by the speed and scale of the Posteros platform, SABs allow teams to identify potential gaps, risks, or misalignment before investing time and resources in live stakeholder engagements.
Traditional advisory boards are resource-intensive and fixed in scope; SABs, on the other hand, are flexible, repeatable, and cost-effective.
This makes SABs especially well-suited for emerging biopharma and biotech companies, where limited budgets and smaller teams make traditional advisory boards harder to justify, even when strategic input is needed.
"Simulated advisory boards give our clients the freedom to explore, challenge, and refine strategy before they ever walk into a live room. That’s powerful."
— Yesim Ilkin, Senior Engagement Manager, Strategic Consulting
Strategic use cases for simulated advisory boards
SABs can be used all across the product lifecycle, but they’re especially powerful in:
- Pre-Launch Planning: Explore unmet needs, refine value propositions, and test stakeholder reactions to pivotal trial data.
- Evidence Generation: Identify key data gaps, prioritize endpoints based on stakeholder perspectives, and assess KOL appetite for novel mechanisms.
- HCP Engagement Strategy: Uncover communication gaps, compare regional variations in perception, and align on tone and format for educational tools.
- Post-Launch Feedback Loops: Respond quickly to real-world evidence trends, refine medical education content, and pressure-test new indications or label expansions.
Medical AI guided by human expertise
What sets SABs apart isn’t just the technology, but how it’s deployed. The Posteros platform was purpose-built for biopharma and biotech. Its simulation engine constructs synthetic expert personas from the ground up – drawing on published literature, clinical guidelines, and document debates within each specialty. Its simulated board members represent the distinct perspectives of real-world specialists. Critically, all simulated responses are grounded in evidence with scientific claims validated against published research using formal evidence-assessment frameworks.
The real differentiator, however, is the integration of this technology with our deeply experienced strategic consultants. Drawing on years of advisory experience, they moderate simulations, curate inputs, validate outputs, and translate insights into guidance that is credible, relevant, and actionable for commercialization. Combined intelligence, working at its best.
"This isn’t standard AI. It’s a medically fluent simulation that we shape, steer, and interpret - just like we would with a real advisory board."
— Rich Gorman, President, Strategic Consulting
Simulated advisory boards scale to your needs
Simulated advisory boards don’t have to replace live advisory boards, but for many smaller or emerging companies, they may be the most practical option.
Whether you’re in early launch planning, preparing for funding discussions, or navigating a critical inflection point, SABs provide a cost-effective, scalable way to get high-quality, medically grounded insights when you need them most.
And when a live advisory board does make sense, SABs can still serve a powerful purpose, helping teams align on key questions, uncover blind spots, and make the most of limited time with real-world experts.
Whether you have a novel or well-established company, simulated advisory boards can provide a solution built to match the pace and pressure of emerging biopharma and biotech needs.